- Home
- JRVR vs ORGO Comparison
JRVR vs ORGO Comparison
Compare JRVR & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRVR | ORGO |
|---|---|---|
| Founded | 2002 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 239.3M |
| IPO Year | 2014 | 2016 |
Fundamental Metrics
Financial Performance| Metric | JRVR | ORGO |
|---|---|---|
| Price | $4.35 | $1.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.33 | ★ $8.50 |
| AVG Volume (30 Days) | 235.2K | ★ 878.3K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | 125.82 | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $687,614,000.00 | $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.61 | $26.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $3.76 | $1.54 |
| 52 Week High | $7.20 | $7.08 |
Technical Indicators
Market Signals| Indicator | JRVR | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 27.54 |
| Support Level | $4.35 | N/A |
| Resistance Level | $4.36 | $2.64 |
| Average True Range (ATR) | 0.16 | 0.14 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 47.69 | 25.35 |
Price Performance
Historical ComparisonAbout JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.